Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
出版年份 2021 全文链接
标题
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
作者
关键词
-
出版物
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-12
DOI
10.1007/s12325-021-01710-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
- (2020) W. Timothy Garvey et al. DIABETES CARE
- Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
- (2020) Thomas A. Wadden et al. Obesity
- Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
- (2020) Tina K. Thethi et al. DIABETES OBESITY & METABOLISM
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
- (2020) Martin Friedrichsen et al. DIABETES OBESITY & METABOLISM
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- (2019) V. R Aroda et al. DIABETES & METABOLISM
- Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study
- (2019) Richard E. Pratley et al. DIABETES OBESITY & METABOLISM
- Cardiovascular risk and obesity
- (2019) C. Cercato et al. Diabetology & Metabolic Syndrome
- GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones and Regional Body Fat Stores in Adults with Obesity
- (2019) Hoda Kadouh et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- PROVIDER PRACTICE HABITS AND BARRIERS TO CARE IN OBESITY MANAGEMENT IN A LARGE MULTICENTER HEALTH SYSTEM
- (2018) Rebecca Simon et al. Endocrine Practice
- Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
- (2018) Greer Waldrop et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Maintenance of Lost Weight and Long-Term Management of Obesity
- (2018) Kevin D. Hall et al. MEDICAL CLINICS OF NORTH AMERICA
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study
- (2017) Lee M. Kaplan et al. Obesity
- Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial
- (2017) Malin Nylander et al. REPRODUCTIVE BIOMEDICINE ONLINE
- Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity
- (2016) Faidon Magkos et al. Cell Metabolism
- Obesity and Cardiovascular Disease
- (2016) Francisco B. Ortega et al. CIRCULATION RESEARCH
- Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data
- (2016) Michael E. Trautmann et al. CLINICAL THERAPEUTICS
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Central nervous system regulation of eating: Insights from human brain imaging
- (2016) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s
- (2016) Catherine E. Thomas et al. Obesity
- Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From aDiabetes CareEditors’ Expert Forum
- (2015) William T. Cefalu et al. DIABETES CARE
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA
- (2015) Charles Baum et al. PHARMACOECONOMICS
- Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
- (2014) E W Iepsen et al. INTERNATIONAL JOURNAL OF OBESITY
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Long-term Drug Treatment for Obesity
- (2013) Susan Z. Yanovski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Long-Term Persistence of Hormonal Adaptations to Weight Loss
- (2011) Priya Sumithran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity
- (2010) J. G. Kang et al. DIABETES OBESITY & METABOLISM
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- Management of gallstones and gallbladder disease in patients undergoing gastric bypass
- (2010) Bernabé M Quesada WORLD JOURNAL OF GASTROENTEROLOGY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
- (2009) Prospective Studies Collaboration LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More